Evidence map›Paper›PMID 24083393›Full record

ArticleLipids in health and disease2013

Protective effect of the omega-3 polyunsaturated fatty acids: Eicosapentaenoic acid/Docosahexaenoic acid 1:1 ratio on cardiovascular disease risk markers in rats.

Laura Lluís, Núria Taltavull, Mònica Muñoz-Cortés, Vanesa Sánchez-Martos, Marta Romeu, Montse Giralt, Eunice Molinar-Toribio, Josep Lluís Torres, Jara Pérez-Jiménez, Manuel Pazos and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03917940 (The Effect of Omega 3 Fatty Acids on Blood Glucose, Lipids Profile, Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03917940 nacompletednot on this mapstarted 2019, after this paper: background citation

The Effect of Omega 3 Fatty Acids on Blood Glucose, Lipids Profile, Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride

TypeinterventionalSponsorDamanhour UniversityRan2019 to 2020Enrolled70ConditionsDiabetic PatientsArmsOmega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral, Glimepiride
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 67 citations in OpenAlex.

  1. Dietary Intake ofNutrients · 2021
    Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Laura LluísUnit of Pharmacology, Faculty of Medicine and Health Sciences, Rovira i Virgili University, Sant Llorenç, 21, 43201 Reus, Spain. mariarosa.nogues@urv.cat.
Núria Taltavull
Mònica Muñoz-Cortés
Vanesa Sánchez-Martos
Marta Romeu
Montse Giralt
Eunice Molinar-Toribio
Josep Lluís Torres
Jara Pérez-Jiménez
Manuel Pazos
Lucía Méndez
José M Gallardo
Isabel Medina
M Rosa Nogués
Universidad Rovira i Virgili · ESInstituto de Investigacións Mariñas · ESInstitute of Advanced Chemistry of Catalonia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh consumption of fish carries a lower risk of cardiovascular disease as a consequence of dietary omega-3 long chain polyunsaturated fatty acid (n-3 PUFA; especially EPA and DHA) content. A controversy exists about the component/s responsible of these beneficial effects and, in consequence, which is the best proportion between both fatty acids. We sought to determine, in healthy Wistar rats, the proportions of EPA and DHA that would induce beneficial effects on biomarkers of oxidative stress, and cardiovascular disease risk.

methodsFemale Wistar rats were fed for 13 weeks with 5 different dietary supplements of oils; 3 derived from fish (EPA/DHA ratios of 1:1, 2:1, 1:2) plus soybean and linseed as controls. The activities of major antioxidant enzymes (SOD, CAT, GPX, and GR) were determined in erythrocytes and liver, and the ORAC test was used to determine the antioxidant capacity in plasma. Also measured were: C reactive protein (CRP), endothelial dysfunction (sVCAM and sICAM), prothrombotic activity (PAI-1), lipid profile (triglycerides, cholesterol, HDLc, LDLc, Apo-A1, and Apo-B100), glycated haemoglobin and lipid peroxidation (LDL-ox and MDA values).

resultsAfter three months of nutritional intervention, we observed statistically significant differences in the ApoB100/ApoA1 ratio, glycated haemoglobin, VCAM-1, SOD and GPx in erythrocytes, ORAC values and LDL-ox. Supplementation with fish oil derived omega-3 PUFA increased VCAM-1, LDL-ox and plasma antioxidant capacity (ORAC). Conversely, the ApoB100/ApoA1 ratio and percentage glycated haemoglobin decreased.

conclusionsOur results showed that a diet of a 1:1 ratio of EPA/DHA improved many of the oxidative stress parameters (SOD and GPx in erythrocytes), plasma antioxidant capacity (ORAC) and cardiovascular risk factors (glycated haemoglobin) relative to the other diets.

Indexed as

AnimalsApolipoproteinsCardiovascular DiseasesCatalaseCholesterol, HDLCholesterol, LDLC-Reactive ProteinDietDocosahexaenoic AcidsEicosapentaenoic AcidErythrocytesFemaleGlutathione PeroxidaseGlutathione ReductaseGlycated HemoglobinLipid PeroxidationApolipoproteinsCatalaseCholesterol, HDLCholesterol, LDLC-Reactive ProteinDocosahexaenoic AcidsEicosapentaenoic AcidGlutathione PeroxidaseGlutathione ReductaseGlycated HemoglobinLipoproteins, LDLMalondialdehydeoxidized low density lipoproteinSuperoxide DismutaseTriglycerides

Identifiers

PMID24083393
PMCPMC3850782
OpenAlexW1983875110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.